On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Food and Drug Administration (FDA) draft guidance on the use of bulk substances under Section 503B of the Federal Food, Drug, and Cosmetic Act. HSCA represents the nation’s leading healthcare group purchasing organizations (GPOs), the sourcing and purchasing partners to virtually all of America’s 7,000+ hospitals.